The long-term influence of therapeutic interventions in asthma with emphasis on inhaled steroids and early disease

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 5, 1998, Pages 133-140

  Haahtela, T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CROMONE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; TERBUTALINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; ADULT DISEASE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMMUNOTHERAPY; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; MAINTENANCE THERAPY; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0031734818     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.028s5133.x     Document Type: Conference Paper

References (65)

1. Asthma Programme in Finland 1994-2004. Ministry of Social Affairs and Health. Clin Exp Allergy 1996; 1 (Suppl): 1-24.
2. Larsson L, Boethius G, Uddenfeldt M. Differences in utilisation of asthma drugs between two neighbouring Swedish provinces: relation to prevalence of obstructive airways disease. Thorax 1994; 49:41-9.
3. Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640-7.
4. Panhuyesen CIM, Vonk JM, Koeter GH, et al. Adult patients may outgrow their asthma. A 25-year follow-up study. Am J Respir Crit Care Med 1997; 155:1267-72.
5. Brown JP, Greville WH, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984; 39:131-6.
6. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70:171-9,
7. Sears MR. Growing up with asthma. Br Med J 1994; 309:72-3.
8. British Asthma Guidelines Co-ordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52:81-24.
9. Expert panel report II, guidelines for the diagnosis and management of asthma. United States National Institutes of Health 1997.
10. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32-42.
11. Jeffery PK, Godfrey RW, Ädelroth E et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 1992; 145:890-9.
12. Djukanovic R, Wilson JW, Britten KM et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-74.
13. Juniper EF, Kline PA, Vanzieleghem MA, O'Byrne PM, Hargreave FE. Reduction of budesonide after a year of increased use:a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991; 87:483-9.
14. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Kerrebijn KF. Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Eur Respir J 1994; 7:63-8.
15. Lundgren R, Soderberg M, Horstedt P, Stenling R. Morphological studies of bronchial biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1:883-9.
16. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864-71.
17. Boulet L, Belanger M, Carrier G. Airway responsiveness and bronchial wall thickness in asthma with and without fixed airflow obstruction. Am J Respir Crit Care Med 1995; 152:865-71.
18. Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996; 51:496-502.
19. Chetta A, Foresi A, Del Donno M, et al. Bronchial responsiveness to distilled water and metacholine and its relationship to inflammation and remodelling of the airways in asthma. Am J Respir Crit Care Med 1996; 153:910-7.
20. Sont JK, van Krieken JHJM, Evertse CE, Neeskens P, Willems LNA, Sterk PJ. Additional reduction in airway subepithelial reticular layer thickness can be obtained by a treatment strategy aimed at improving bronchial hyperresponsiveness (BHR) in asthma. Am J Respir Crit Care Med 1997; 155 (Suppl. 4):A502.
21. Juniper EF, Kline PA, Vanzielegheim MA, Ramsdale MH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142:832-6.
22. Haahtela T, Järvinen M, Kava T, et al. Comparison of a B2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388-92.
23. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32-42.
24. Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331:700-5.
25. Kerstjens HAM, Brand PLP, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327:1413-9.
26. Overbeek SE, Kerstjens HAM, Bogaard JM, Mulder PGH, Postma DS. Is delayed introduction of inhaled corticosteroid harmful in patients with obstructive airway disease? Chest 1996; 110:35-41.
27. Osterman K, Carlholm M, Ekelund J, et al. Effects of 1-year daily treatment with 400 μg budesonide (Pulmicort® Turbuhaler® in newly diagnosed asthmatics. Eur Respir J 1997; 10:2210-5.
28. Selroos O, Pietinalho A, Löfroos A-B, Riska H. Effect of early vs.late intervention with inhaled corticosteroids in asthma. Chest 1995; 108:1228-34.
29. O'Byrne PM, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J. The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Resp J 1996; 3:169-75.
30. Bousquet J, Knani J, Henry C et al. Undertreatment in a nonselected population of adult patients with asthma. J Allergy Clin Immunol 1996; 98:514-21.
31. Ferrante E, Muzzolon R, Fuso L, Corbo GM, Pistellini R, Ciappi G. Bronchial asthma: still an inadequately assessed and improperly treated disease. J Asthma 1994; 31:117-21.
32. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. Jama 1997; 277:887-91.
33. Van Ganse E, Hubloue I, Vincken W, Leufkens HG, Gregoire J, Ernst P. Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. Eur J Clin Pharmacol 1997; 51:449-54.
34. Wennergren G, Kristjánsson S, Strannegård I-L. Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in the prevalence of asthma. J Allergy Clin Immunol 1996; 97:742-8.
35. Ernst P, Spitzer WO, Suissa S et al. Risk of fatal asthma and near-fatal asthma in relation to inhaled corticosteroid use. Jama 1992; 268:3462-4.
36. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88:373-81.
37. Konig P, Shaffer J. The effect of drug therapy on long-term outcome of childhood asthma: a possible preview of the international guidelines. J Allergy Clin Immunol 1996; 98:1103-11.
38. Oswald H, Phelan PD, Lanigan A, et al. Childhood asthma and lung function in mid-adult life. Pediatr Pulmonol 1997; 23:14-20.
39. Kraan J, Koeter GH, van der Mark ThW et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76:628-36.
40. Jenkins CR, Woolcock AJ. Effect of prednisone and bechlomethasone dipropionate on airway responsiveness in asthma: a comparative study. Thorax 1988; 43:378-84.
41. Laitinen LA, Laitinen A, Heino M, Haahtela T. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis 1992; 143:423-7.
42. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147:697-704.
43. Van Schayck CP, van den Broek PJ, den Otter JJ, van Herwaarden CL, Molema J, van Weel C. Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible? Jama 1995; 274 (2):161-4.
44. Waalkens HJ, van Essen Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, Kerrebijn KK. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993; 148:1252-7.
45. Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337:1659-65.
46. Crane J, Burgess C, Pearce N et al. The β2-agonist controversy: a perspective. Eur Respir Rev 1993; 15:475-82.
47. Woolcock A, Lundbäck B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-8.
48. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-11.
49. Verberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997; 156:688-95.
50. Cheung DM, Timmers AH, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting β2-agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198-203.
51. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma. J Respir Crit Care Med 1995; 152:1170-4.
52. Sullivan O, Bekir S, Jaffar Z et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343:1006-8.
53. Evans DJ, Taylor DA, Zetterström O, Fan Chung K, O'Connor BB, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337:1412-8.
54. Barnes PJ, Holgate ST, Laitinen LA, Pauwels R. Asthma mechanisms, determinants of severity and treatment: the role of of nedocromil sodium. Clin Exp Allergy 1995; 25:771-87.
55. Svendsen UG, Frolund L, Madresn F, Nielsen NH, Holstein RN, Weeke B. A comparison of the effects of sodium cromoglycate and beclomethasone dipropionate on pulmonary function and bronchial hyperreactivity in subjects with asthma. J Allergy Clin Immunol 1987; 80:68-74.
56. Reiss TF, White R, Noonan G, Korenblat P, Hess J, Shingo S. Montelukast (MK-0476), A CysLT1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Eur Respir J 1997; 10:4375 (Abstract).
57. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch Intern Med 1998; 158:1213-20. (Abstract).
58. Hedlin G, Heilborn H, Lilja G et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96:879-85.
59. Shaikh WA. Immunotherapy vs. inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. Clin Exp Allergy 1997; 27:1279-84.
60. Torres Costa JC, Placido JL, Moreira Silva JP et al. Effects of immunotherapy on symptoms, PEFR, spirometry and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy. Allergy 1996; 51:238-44.
61. Valovirta E. Capacity of specific immuntherapy in prevention of allergic asthma in children:the preventive allergy treatment study (PAT). J Invest Allergol Clin Immunol 1997; 7:369-70.
62. Danzig M, Cuss F. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy 1997; 52:787-94.
63. Haahtela T. Airway remodelling takes place in asthma-what are the clinical implications? Clin Exp Allergy 1997; 27:351-3.
64. Fahy JV, Fleming E, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-34.
65. Boulet L-P, Chapman KR, Cote J, et al.. Inhibitory effect of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835-40.